Despite encouraging clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant difficulty from pharmacy benefit managers. The companies are https://karimaqkx089038.blogoxo.com/42417921/company-s-vyndamax-faces-is-dealing-with-managed-care-organization-hurdles-the-review-of-access-disputes